secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Oncology Therapeutics, Inc. (BBOT)
CIK:        0001869105
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001193125-26-191512
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Oncology enters consulting agreement with former CEO Eli Wallace; equity vesting continues for 12 months
--------------------------------------------------------------------------------

- Dr. Wallace provides R&D advisory services for 12 months retroactive to April 21, 2026.
- Compensation: continued vesting of outstanding equity awards subject to service through each vesting date.
- Vested stock options exercisable up to 2 years after consulting termination or original expiry, whichever earlier.
- Wallace also receives Tier 1 severance benefits under the Executive Severance Plan via Separation Agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/0001193125-26-191512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1869105/000119312526191512/d68319d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-191512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer